AbbVie plans to it increase its earnings per share and elevates the market value of the remaining shares, as it has authorized a $5 billion increase to AbbVie’s existing stock repurchase program.
The company said that purchases may be made from time to time in management’s discretion.
“The stock repurchase authorization permits shares to be repurchased in open market or private transactions, has no time limit and may be discontinued at any time,” AbbVie’s press release reads.